Locations:
Search IconSearch

Tag: myelodysplastic syndrome (MDS)

Genomic profiling
June 10, 2025/Cancer

Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

Immune system
October 20, 2023/Cancer/Research

The Role of Immune Escape in Post-Transplant Leukemia Relapse

Immunological pressure driving genetic mutations

Lab equipment centrifuging blood. Concept image of a blood test.3d rendering.
February 3, 2022/Cancer/Blood Cancers

Newly Identified Risk Factors Help Predict How Aplastic Anemia Can Become Malignant

Study reveals characteristics that may spark the development of myelodysplastic syndrome and acute myeloid leukemia

leukemia_650x450

Succession of Molecular Lesions Critical to Leukemia Disease Development

Mutational pattern in MDS is not random, study finds

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

18-CCC-5885-DNA-PTA-test-650×450
January 15, 2020/Cancer/Research

New Clinic Tackles Mutations That Increase Risk of Blood Cancers and Heart Disease

CHIP Clinic's goals: Research, preventive care

Cancer cells
December 2, 2018/Cancer/Research

The Next Step in Immunotherapy for Myeloid Hematologic Malignancies

Study explores atezolizumab for myelodysplastic syndrome

BackPage 1 of 1Next

Advertisement

Ad